No insider purchase over the last 90 days. The latest, by Diamantis Christopher Eric, was filed 19 Jul 2016.
Rennova Health, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Rennova Health, Inc. in twelve months, the latest record being from 27 September 2021.
The full history, which starts in 2006, counts 28 purchases against 58 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2023 · cache
25 of 158 declarations
Rennova Health, Inc. is a U.S.-listed healthcare company trading on the OTC market (OTCID: RNVA), historically followed by investors who track highly speculative micro-cap names in the American healthcare space; the company has also been associated at various points with Nasdaq-related filings and capital-market activity. Its corporate headquarters is in West Palm Beach, Florida, United States. From a business-model perspective, Rennova has evolved around integrated solutions for healthcare providers, combining diagnostics, supportive software, and, at different stages of its recent history, hospital-related assets. Recent SEC disclosures describe Rennova as a provider of diagnostics and supportive software solutions to healthcare providers, with an emphasis on helping improve the patient experience and clinical efficiency. The company was launched in 2015 following a merger involving Medytox Solutions and CollabRx, and its subsequent history has been marked by repeated strategic adjustments in response to a challenging reimbursement and financing environment.
Rennova’s core business historically centered on clinical laboratory operations, particularly urine and toxicology testing for physicians, clinics, and rehabilitation facilities. Earlier company materials also referenced supportive software offerings such as electronic health records, laboratory information systems, and medical billing services. More recent official communications frame the company more broadly as a vertically integrated healthcare platform that aims to pair diagnostics with software tools in order to deliver a more cohesive offering to providers. That combination has been the company’s main strategic thread, even as the asset mix has shifted over time.
Competitively, Rennova operates as a small-cap specialty player in a fragmented market dominated by much larger and better-capitalized diagnostic chains, hospital operators, and healthcare software vendors. It does not compete with the scale, balance-sheet strength, or brand recognition of major U.S. healthcare incumbents. Instead, its value proposition has been centered on niche clinical capabilities, operational flexibility, and the potential to monetize specialized healthcare workflows. This also means the company remains highly exposed to reimbursement dynamics, regulatory pressure, execution risk, and funding constraints.
A key recent development was the June 2024 announcement of stock exchange agreements with FOXO Technologies involving two operating subsidiaries, as part of a broader restructuring of Rennova’s healthcare assets. SEC filings in 2025 confirm that the company remains headquartered in West Palm Beach and continue to reflect a healthcare-focused profile anchored in diagnostics and related services. For investors in French-speaking markets, Rennova Health should therefore be viewed as a special-situation name: a long-history U.S. healthcare company with a complex corporate evolution, very small market capitalization, and a risk profile that is materially higher than that of established large-cap healthcare peers.
Purchases our model currently ranks for the recommendations list.
All recommendations